Isoquercetin activates alternative BA biosynthesis pathways and inhibits intestinal FXR-FGF15 signaling, which reduces cholesterol and triglyceride levels in the liver, improving NAFLD (Zhang et al., 2023). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.